Object: In this open trial the efficacy and safety of clozapine in
treatment-resistant schizophrenic patients were investigated.
Method: Treatment-resistant 29 schizophrenic patients were
followed-up for three years. Drug efficacy was assessed by means
of the BPRS, SAPS, and SANS. Side effects were rated with
UKU side effect scale, EEG, biochemical and hormone analysis.
Results and Conclusion: At the end of 3rd year we found a decrease
of 41.1% in BPRS score, %49.0 in SAPS score, and %33.6
in SANS score compared with pretreatment scores. The most
common side effects were weight gain, hypersalivation, sedation,
and EEG abnormalities. The agranulocytosis, which was
reported as the most significant side effect, was not observed in
this study group.
clozapine, treatment-resistant schizophrenia, three years follow-up